monochromasia

(redirected from achromatopsia)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.

monochromasia

[‚män·ə·krə′mā·zhə]
(medicine)
Complete color blindness in which all colors appear as shades of gray. Also known as monochromatism.
Mentioned in ?
References in periodicals archive ?
Under preclinical studies in dog and sheep models of achromatopsia, the animals demonstrated that they are better able to navigate a maze after receiving gene therapy that delivers a functional copy of CNGA3 or CNGB3, stated the company.
The report reviews key players involved Achromatopsia therapeutics and enlists all their major and minor projects
There is no treatment for Achromatopsia, although deep red tinted spectacles or contact lenses can reduce symptoms of light sensitivity.
Table 1 Eye-related photophobia Disorder Additional signs/symptoms Mechanism Achromatopsia Reduced vision, Stimulation of light hemeralopia, nystagmus, sensitive cells in retina iris dysfunction and iris Aniridia Nystagmus, low vision, Reduction in control of buphthalmos, cataract light entering eye.
Speaking to the Daily Post last night, she said: "I knew the signs of achromatopsia because two of my nephews already had it, and like Cameron, their problems began with nystagmus - an involuntary movement of the eyes.
Achromatopsia is an inherited condition that presents at birth with impaired visual acuity, lack of color discrimination and extreme light sensitivity resulting in daytime blindness.
M2 EQUITYBITES-November 24, 2015-AGTC awarded US FDA's orphan drug designation for gene therapy for inherited retinal disease achromatopsia
The resulting close genetic ancestry of the islanders meant that the prevalence of achromatopsia increased from a typical one in 40,000 to almost one in 12.
Diagnosed with achromatopsia at eight weeks old, the rare genetic condition means she is registered blind.
The schoolgirl from Kinmel Bay suffers from achromatopsia, a rare genetic condition that leaves her completely colourblind.
Colour identification and colour constancy are impaired in a patient with incomplete achromatopsia associated with prestriate cortical lesions.
The investment funds will be used by AGTC to complete the next phase in human clinical trials for its gene therapy treatments for Alpha-1 Antitrypsin Deficiency (Alpha-1) a form of emphysema and Leber's Congenital Amaurosis (LCA) a form of childhood blindness, and preclinical development of gene therapy treatment for Achromatopsia, a form of daytime blindness.